| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | D Allan Butterfield | Q66912067 |
| P2093 | author name string | Elizabeth Head | |
| Marzia Perluigi | |||
| Fabio Di Domenico | |||
| Aaron M Swomley | |||
| P2860 | cites work | Protein oxidation and degradation during postmitotic senescence. | Q40363959 |
| Effect of acrolein and glutathione depleting agents on thioredoxin | Q40511973 | ||
| Redox signaling: nitrosylation and related target interactions of nitric oxide | Q40630842 | ||
| Proteolysis in cultured liver epithelial cells during oxidative stress. Role of the multicatalytic proteinase complex, proteasome. | Q41370949 | ||
| Biochemistry and pathology of radical-mediated protein oxidation | Q41481967 | ||
| Oxidative stress hypothesis in Alzheimer's disease | Q41482152 | ||
| Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment | Q42170202 | ||
| Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. | Q42484252 | ||
| Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process | Q42862763 | ||
| Gene-dosage effects in Down syndrome and trisomic mouse models | Q21194863 | ||
| Identification of regulators of chaperone-mediated autophagy | Q24297535 | ||
| Activation of chaperone-mediated autophagy during oxidative stress | Q24562065 | ||
| Mammalian autophagy: core molecular machinery and signaling regulation | Q24595447 | ||
| One step at a time: endoplasmic reticulum-associated degradation | Q24658302 | ||
| The role of lipid peroxidation in neurological disorders | Q26829767 | ||
| Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities | Q26863005 | ||
| The chemical biology of S-nitrosothiols | Q27007846 | ||
| Neurological phenotypes for Down syndrome across the life span | Q27025698 | ||
| Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies | Q27693922 | ||
| Free radicals in the physiological control of cell function | Q27860480 | ||
| Aging: a theory based on free radical and radiation chemistry | Q27860549 | ||
| Oxidants, oxidative stress and the biology of ageing | Q28131725 | ||
| Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease | Q28259585 | ||
| Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases | Q28269333 | ||
| Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling | Q28388989 | ||
| NOX enzymes and the biology of reactive oxygen | Q29547517 | ||
| The role of autophagy in neurodegenerative disease | Q29614834 | ||
| Oxidative stress and neurodegeneration: where are we now? | Q29617324 | ||
| Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? | Q29619535 | ||
| Protein oxidation in aging and the removal of oxidized proteins. | Q30426117 | ||
| Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. | Q30446460 | ||
| Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies | Q30655091 | ||
| Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome | Q30789931 | ||
| Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. | Q31101732 | ||
| Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease | Q33322972 | ||
| Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. | Q33431516 | ||
| Protein carbonylation. | Q33649892 | ||
| Cell signaling by protein carbonylation and decarbonylation | Q33661117 | ||
| Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease | Q33915362 | ||
| The ubiquitin-proteasome pathway and synaptic plasticity | Q33994715 | ||
| ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome | Q33999948 | ||
| RNA oxidation adducts 8-OHG and 8-OHA change with Aβ42 levels in late-stage Alzheimer's disease | Q34031631 | ||
| In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. | Q42920869 | ||
| Protein oxidation in the brain in Alzheimer's disease | Q43540892 | ||
| V-ATPase engagement in autophagic processes | Q43653039 | ||
| The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. | Q43681037 | ||
| Oxidative damage is the earliest event in Alzheimer disease | Q43696731 | ||
| Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome | Q43906174 | ||
| Fructose-1,6-bisphosphate preserves intracellular glutathione and protects cortical neurons against oxidative stress | Q44265105 | ||
| Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases | Q44727052 | ||
| Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. | Q44795484 | ||
| Increased lipid peroxidation in Down's syndrome mouse models. | Q45914918 | ||
| In vivo protection of synaptosomes from oxidative stress mediated by Fe2+/H2O2 or 2,2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate | Q46394465 | ||
| Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease | Q46483089 | ||
| Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. | Q46685854 | ||
| Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome | Q46751023 | ||
| Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. | Q46792024 | ||
| Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach | Q46868947 | ||
| Redox proteomics: from protein modifications to cellular dysfunction and disease | Q46966345 | ||
| Increased amyloid beta protein levels in children and adolescents with Down syndrome. | Q48286653 | ||
| Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. | Q48331200 | ||
| Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? | Q48407483 | ||
| Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. | Q48482673 | ||
| A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. | Q48824580 | ||
| Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. | Q51034709 | ||
| Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. | Q53082667 | ||
| Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome | Q57342126 | ||
| Oral administration of methylglyoxal leads to kidney collagen accumulation in the mouse | Q58365446 | ||
| Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid | Q61193613 | ||
| Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein | Q73204871 | ||
| Oxidative stress in neurodegenerative disorders | Q79223726 | ||
| Immunocytochemical and lectin histochemical studies of plaques and tangles in Down's syndrome patients at different ages | Q93530363 | ||
| Beta-amyloid, oxidative stress and down syndrome | Q36683240 | ||
| Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. | Q36939000 | ||
| Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression | Q37111515 | ||
| Oxidative stress hypothesis in Alzheimer's disease: a reappraisal | Q37288063 | ||
| Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options | Q37299615 | ||
| Reactive oxygen species in living systems: source, biochemistry, and role in human disease | Q37413721 | ||
| Relation between gastric cancer and protein oxidation, DNA damage, and lipid peroxidation. | Q37457030 | ||
| Oxidized proteins: mechanisms of removal and consequences of accumulation | Q37458484 | ||
| Comparative proteomic analysis of cysteine oxidation in colorectal cancer patients | Q37462204 | ||
| Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle | Q37509229 | ||
| Nitric oxide in cell survival: a janus molecule | Q37532468 | ||
| Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism | Q37603401 | ||
| Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. | Q37613081 | ||
| Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. | Q37662773 | ||
| Nitric oxide signaling and nitrosative stress in neurons: role for S-nitrosylation | Q37784821 | ||
| Autophagy and misfolded proteins in neurodegeneration | Q37811463 | ||
| Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders | Q37896718 | ||
| Protein-conjugated acrolein as a biochemical marker of brain infarction. | Q37898084 | ||
| Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits | Q37948475 | ||
| Protein homeostasis, aging and Alzheimer's disease | Q37987808 | ||
| Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies | Q38017513 | ||
| Therapeutic induction of autophagy to modulate neurodegenerative disease progression | Q38078803 | ||
| Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases | Q38093796 | ||
| 3-Nitrotyrosine: A biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. | Q38115392 | ||
| Potential synergy between tau aggregation inhibitors and tau chaperone modulators. | Q38138165 | ||
| Protein carbonylation: proteomics, specificity and relevance to aging. | Q38151609 | ||
| Redox proteomics and the dynamic molecular landscape of the aging brain | Q38174406 | ||
| Mass spectrometry and redox proteomics: applications in disease | Q38220377 | ||
| Proteasome inhibitors induce the association of Alzheimer's amyloid precursor protein with Hsc73. | Q38329036 | ||
| Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome | Q39480888 | ||
| Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration | Q34071097 | ||
| The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology | Q34109999 | ||
| Proposed role of primary protein carbonylation in cell signaling | Q34147499 | ||
| Cellular strategies of protein quality control | Q34199521 | ||
| Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia | Q34246990 | ||
| Strategies of antioxidant defense | Q34306493 | ||
| Dependence of H2O2 formation by rat heart mitochondria on substrate availability and donor age. | Q34419427 | ||
| Relationship between susceptibility to protein oxidation, aging, and maximum life span potential of different species | Q34450841 | ||
| Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide | Q34456855 | ||
| Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. | Q34590312 | ||
| Genetic and host factors for dementia in Down's syndrome | Q34620232 | ||
| Mitochondrial dysfunction and Down's syndrome. | Q34811509 | ||
| Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death | Q34976924 | ||
| The lipid peroxidation product 4-hydroxy-2-nonenal: Advances in chemistry and analysis | Q34984799 | ||
| Protein S-nitrosylation in health and disease: a current perspective | Q35020178 | ||
| Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism | Q35130116 | ||
| A review of the mammalian unfolded protein response. | Q35354864 | ||
| Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease | Q35359220 | ||
| Peroxynitrite reactivity with amino acids and proteins | Q35602249 | ||
| Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia | Q35606429 | ||
| Glucose metabolism and insulin receptor signal transduction in Alzheimer disease | Q35749640 | ||
| Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. | Q35869366 | ||
| Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. | Q35916225 | ||
| Oxidative Stress and Mitochondrial Dysfunction in Down's Syndrome: Relevance to Aging and Dementia | Q35955120 | ||
| Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease | Q35997824 | ||
| Brain metabolic dysfunction at the core of Alzheimer's disease | Q35997881 | ||
| The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity | Q36023881 | ||
| Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. | Q36390685 | ||
| Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome | Q36428399 | ||
| Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease | Q36538283 | ||
| Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics | Q36543890 | ||
| DNA oxidation in Alzheimer's disease | Q36620586 | ||
| Adaptive downregulation of mitochondrial function in down syndrome | Q36632280 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neurodegeneration | Q1755122 | ||
| P304 | page(s) | 177-189 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. | |
| P478 | volume | 463 |
| Q64272039 | Acidifying Endolysosomes Prevented Low-Density Lipoprotein-Induced Amyloidogenesis |
| Q37141585 | Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype |
| Q37102001 | Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology |
| Q46778500 | Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. |
| Q36367840 | Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease |
| Q48444907 | Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. |
| Q37105161 | Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins |
| Q38838536 | Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease |
| Q39433562 | Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism. |
| Q98177367 | Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions |
| Q101051196 | Dynamic changes in the brain protein interaction network correlates with progression of Aβ42 pathology in Drosophila |
| Q49497621 | Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. |
| Q50034506 | Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models. |
| Q47960190 | Exosomal biomarkers in Down syndrome and Alzheimer's disease |
| Q39006663 | HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology |
| Q58609012 | Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome |
| Q28077589 | Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration |
| Q91674752 | Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) |
| Q88957780 | Lysosome trafficking and signaling in health and neurodegenerative diseases |
| Q91653370 | Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome |
| Q36767908 | Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress |
| Q36539454 | Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? |
| Q46266115 | Neuroprotective effects of hydrogen sulfide on sodium azide-induced oxidative stress in PC12 cells |
| Q51760895 | Oxidative Stress, Amyloid-β Peptide, and Altered Key Molecular Pathways in the Pathogenesis and Progression of Alzheimer's Disease. |
| Q48513955 | Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology. |
| Q39205712 | Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease |
| Q37235572 | Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls. |
| Q96110135 | Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome |
| Q92399660 | Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome |
| Q47761796 | Significance of Mitochondrial Protein Post-translational Modifications in Pathophysiology of Brain Injury |
| Q38815881 | Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies |
| Q36593201 | The neuropathology and cerebrovascular mechanisms of dementia |
| Q37640781 | Vincamine Alleviates Amyloid-β 25-35 Peptides-induced Cytotoxicity in PC12 Cells |
| Q47953822 | mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia |
Search more.